Lv4
740 积分 2022-12-16 加入
Epigallocatechin gallate alleviates Non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4
14小时前
已完结
Pathophysiology roles for adenosine 2A receptor in obesity and related diseases
2个月前
已完结
The GPR40 novel agonist SZZ15‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice
2个月前
已完结
Diosgenin ameliorating non‐alcoholic fatty liver disease via Nrf2‐mediated regulation of oxidative stress and ferroptosis
2个月前
已完结
Daphnetin ameliorates hepatic steatosis by suppressing peroxisome proliferator-activated receptor gamma (PPARG) in ob/ob mice
2个月前
已完结
Caveolin-1 ameliorates hepatic injury in non-alcoholic fatty liver disease by inhibiting ferroptosis via the NOX4/ROS/GPX4 pathway
2个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
3个月前
已完结
Natural history of metabolic dysfunction-associated steatotic liver disease
3个月前
已完结
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
3个月前
已完结
Current status and future trends of the global burden of MASLD
3个月前
已完结
皖公网安备34019202002308
